Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 49 articles:
HTML format
Text format



Single Articles


    April 2018
  1. GANDHI L, Rodriguez-Abreu D, Gadgeel S, Esteban E, et al
    Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018 Apr 16. doi: 10.1056/NEJMoa1801005.
    PubMed     Text format     Abstract available


  2. FORDE PM, Chaft JE, Smith KN, Anagnostou V, et al
    Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    N Engl J Med. 2018 Apr 16. doi: 10.1056/NEJMoa1716078.
    PubMed     Text format     Abstract available


  3. HELLMANN MD, Ciuleanu TE, Pluzanski A, Lee JS, et al
    Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
    N Engl J Med. 2018 Apr 16. doi: 10.1056/NEJMoa1801946.
    PubMed     Text format     Abstract available


  4. MAMDANI H, Grethlein SJ
    Pulmonary Metastases from Chondroblastic Osteosarcoma.
    N Engl J Med. 2018;378:1429.
    PubMed     Text format    


    March 2018
  5. CHOI JY, Choi YJ, Shin SW
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1262.
    PubMed     Text format    


  6. ROCA E, Amoroso V, Berruti A
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261-2.
    PubMed     Text format    


  7. WARD MC, Prabhu RS, Burri SH
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261.
    PubMed     Text format    



  8. Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261-1263.
    PubMed     Text format    


  9. WEINSTOCK M, Vaidya A, El-Chemaly S, Godleski J, et al
    The Verge of Collapse.
    N Engl J Med. 2018;378:e18.
    PubMed     Text format    



  10. Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:868-870.
    PubMed     Text format    


  11. SANTONI M, Battelli N, Buti S
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:869.
    PubMed     Text format    


  12. COPUR MD, Gauchan D, Ramaekers R
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:868.
    PubMed     Text format    


    January 2018
  13. POPAT S
    Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:192-193.
    PubMed     Text format    


    November 2017
  14. SORIA JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, et al
    Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Nov 18. doi: 10.1056/NEJMoa1713137.
    PubMed     Text format     Abstract available


  15. SOHAL SS, Walers EH
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1998-9.
    PubMed     Text format    


  16. REN C, Han C, Wang D
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1998.
    PubMed     Text format    


  17. KWON HW, Ham SY, Shin SW
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1997-8.
    PubMed     Text format    


  18. RIZVI NA, Peters S
    Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1986-1988.
    PubMed     Text format    



  19. Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1999.
    PubMed     Text format    


    September 2017
  20. ANTONIA SJ, Villegas A, Daniel D, Vicente D, et al
    Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Sep 8. doi: 10.1056/NEJMoa1709937.
    PubMed     Text format     Abstract available


    August 2017
  21. RECK M, Rabe KF
    Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:849-861.
    PubMed     Text format    


    June 2017
  22. CARBONE DP, Reck M, Paz-Ares L, Creelan B, et al
    First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;376:2415-2426.
    PubMed     Text format     Abstract available


  23. PETERS S, Camidge DR, Shaw AT, Gadgeel S, et al
    Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Jun 6. doi: 10.1056/NEJMoa1704795.
    PubMed     Text format     Abstract available


  24. ROBLES AI, Zenklusen JC
    Seeing the Forest through the Phylogenetic Tree.
    N Engl J Med. 2017;376:2190-2191.
    PubMed     Text format    


    May 2017
  25. NISHINO M, Hatabu H
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1992-3.
    PubMed     Text format    


  26. YIN Y, Li J
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1993.
    PubMed     Text format    



  27. Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1993-4.
    PubMed     Text format    


  28. ZHANG BM, Aleshin A, Lin CY, Ford J, et al
    IDH2 Mutation in a Patient with Metastatic Colon Cancer.
    N Engl J Med. 2017;376:1991-2.
    PubMed     Text format    


    April 2017
  29. JAMAL-HANJANI M, Wilson GA, McGranahan N, Birkbak NJ, et al
    Tracking the Evolution of Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Apr 26. doi: 10.1056/NEJMoa1616288.
    PubMed     Text format     Abstract available


    March 2017
  30. DEFILIPPIS EM, Vaidya A, Ramani S, French C, et al
    Under Pressure.
    N Engl J Med. 2017;376:e23.
    PubMed     Text format    


  31. SORSCHER S
    Pembrolizumab in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;376:996-7.
    PubMed     Text format    



  32. Pembrolizumab in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;376:997.
    PubMed     Text format    


    February 2017
  33. MAOZ A, Rennert G, Gruber SB
    T-Cell Transfer Therapy Targeting Mutant KRAS.
    N Engl J Med. 2017;376:e11.
    PubMed     Text format    


  34. RECH AJ, Vonderheide RH
    T-Cell Transfer Therapy Targeting Mutant KRAS.
    N Engl J Med. 2017;376:e11.
    PubMed     Text format    


  35. ROSENBERG SA, Tran E, Robbins PF
    T-Cell Transfer Therapy Targeting Mutant KRAS.
    N Engl J Med. 2017;376:e11.
    PubMed     Text format    


  36. MOK TS, Wu YL, Ahn MJ, Garassino MC, et al
    Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:629-640.
    PubMed     Text format     Abstract available


    December 2016
  37. TRAN E, Robbins PF, Lu YC, Prickett TD, et al
    T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
    N Engl J Med. 2016;375:2255-2262.
    PubMed     Text format     Abstract available


    October 2016
  38. JOHNSON BE
    Divide and Conquer to Treat Lung Cancer.
    N Engl J Med. 2016.
    PubMed     Text format    


  39. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


    August 2016
  40. CHOY E, Hornicek FJ, Chen YL, Rosenthal DI, et al
    CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 26-2016. A 28-Year-Old Woman with Back Pain and a Lesion in the Lumbar Spine.
    N Engl J Med. 2016;375:779-88.
    PubMed     Text format    


    July 2016
  41. POLLARD JW
    Defining Metastatic Cell Latency.
    N Engl J Med. 2016;375:280-2.
    PubMed     Text format    


    June 2016
  42. SEQUIST LV, Soria JC, Camidge DR
    Update to Rociletinib Data with the RECIST Confirmed Response Rate.
    N Engl J Med. 2016;374:2296-7.
    PubMed     Text format    


    May 2016
  43. SWANTON C, Govindan R
    Clinical Implications of Genomic Discoveries in Lung Cancer.
    N Engl J Med. 2016;374:1864-73.
    PubMed     Text format    


  44. BORDI P, Del Re M, Tiseo M
    Crizotinib Resensitization by Compound Mutation.
    N Engl J Med. 2016;374:1790.
    PubMed     Text format    


  45. SHAW AT, Engelman JA
    Crizotinib Resensitization by Compound Mutation.
    N Engl J Med. 2016;374:1790-1.
    PubMed     Text format    


    February 2016
  46. GYAWALI B, Ota A, Ando Y
    Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016;374:493.
    PubMed     Text format    


  47. HASEGAWA T, Uno H, Wei LJ
    Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016;374:492-3.
    PubMed     Text format    


  48. BORGHAEI H, Brahmer J
    Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016;374:493-4.
    PubMed     Text format    


    January 2016
  49. SHAW AT, Friboulet L, Leshchiner I, Gainor JF, et al
    Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
    N Engl J Med. 2016;374:54-61.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: